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Abstract
Background: Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae have spread worldwide but there 
are few reports on carriage in hospitals in low-income countries. ESBL-producing Enterobacteriaceae (ESBL-PE) have 
been increasingly isolated from nosocomial infections in Antananarivo, Madagascar.
Methods: we conducted a prevalence survey in a pediatric unit from March to April 2008 Patient rectal swabs were 
sampled on the first and the last day of hospitalization. Medical staff and environment were also sampled. Rectal and 
environmental swabs were immediately plated onto Drigalski agar supplemented with 3 mg/liter of ceftriaxon.
Results: Fecal carriage was detected in 21.2% of 244 infants on admission and 57.1% of 154 on discharge, after more 
than 48 hours of hospitalization (p < 0.001). The species most frequently detected on admission were Escherichia coli 
and Klebsiella pneumoniae (36.9%), whereas, on discharge, K. pneumoniae was the species most frequently detected 
(52.7%). ESBL-associated resistances were related to trimethoprim-sulfamethoxazole (91.3%), gentamicin (76.1%), 
ciprofloxacin (50.0%), but not to amikacin and imipenem. The increased prevalence of carriage during hospitalization 
was related to standard antimicrobial therapy.
Conclusion: The significant emergence of multidrug-resistant enteric pathogens in Malagasy hospitals poses a serious 
health threat requiring the implementation of surveillance and control measures for nosocomial infections.
Background
New classes of enzymes conferring resistance to β-lactam
antibiotics have emerged over the last few decades, due to
antibiotic selection pressure; most alarming are the
extended spectrum β-lactamases (ESBLs) produced by
enteric pathogens that have spread worldwide since their
first description in 1983 [1]. Typically, ESBLs hydrolyze
third generation cephalosporins and aztreonam, but not
carbapenems, and are inhibited by clavulanic acid and
tazobactam [2]. ESBL-producing pathogens frequently
exhibit plasmid-encoded multidrug resistance. Therefore,
antibiotic therapy for treating these infections is limited
t o  a  s m a l l  n u m b e r  o f  e x p e n s i v e  d r u g s .  A s  a  r e s u l t  o f
mutations, more than 200 types of ESBLs are currently
described in various species of the Enterobacteriaceae
family and other non enteric organisms, such as
Pseudomonas aeruginosa and  Acinetobacter sp. TEM-
and SHV-type β-lactamases, mainly produced by Kleb-
siella pneumoniae, have spread throughout hospital set-
tings, and CTX-M enzymes, mainly produced by
Escherichia coli, have become predominant in the com-
munity [3,4].
Since the 1990s, nosocomial outbreaks due to ESBL-
producing  Enterobacteriaceae  (ESBL-PE) have been
increasingly reported worldwide, especially in developed
countries [5].
In hospital settings, intestinal carriage is the main res-
ervoir of these organisms. The gut colonization of inpa-
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tients is associated with a high risk for developing self and
cross infections due to ESBL-producers, especially in
long-term care units. Dissemination of ESBL-producing
clones results from the movement of patients between
various units of the same hospital, but also between hos-
pitals, nationally or internationally [6,7]. In low-income
countries, prevalence studies on the carriage of ESBL-
producing Gram negative bacilli (GNB) are scarce,
whereas the burden of linked infections is increasing due
to an absence of expensive second-line antibiotics [8]. A
facility-based study on neonatal sepsis in India showed
that 50% of causative GNB were ESBL-PE [9]. Few studies
have evaluated fecal carriage during non outbreak situa-
tions. Patients colonized at admission can nevertheless
introduce the pathogen into hospital units [4].
ESBL-PEs in Madagascar were initially isolated
between 2005 and 2006 from community-acquired uri-
nary tract infections [10]. They were then isolated during
an epidemic that occurred in two pediatric units in 2006;
more recently, ESBL-PEs have been isolated from several
infections acquired in various surgical and intensive care
units of Antananarivo [11].
This study, conducted in a pediatric department of a
large teaching hospital in Antananarivo, aimed to assess
the levels of ESBL-PE carriage among hospitalized infants
-- on admission and on discharge -- and to determine the
risk factors for colonization and infection.
Methods
Design of the study
Patients <15 years of age hospitalized in the pediatric unit
of Befelatanana hospital in Antananarivo were enrolled,
after receiving parental consent, in a cohort study from
March to April 2008. The unit has a capacity of 22 rooms
and 105 beds managed by a staff of 15 physicians, 22
nurses and 15 employees. For each patient, the demo-
graphic characteristics (age, gender...), medical history
(prior hospitalization, prior invasive devices used...), anti-
biotic therapies, diagnosis on admission and discharge
were recorded. Patient rectal swabs were sampled on the
first and the last day of hospitalization. Rectal swabs were
also sampled among voluntary medical staff during the
same period. Moreover, each week, 20 environmental
sites (table, sink, stethoscopes...) were sampled in the four
care rooms of the unit.
Laboratory methods
Rectal and environmental swabs were immediately plated
onto Drigalski agar supplemented with 3 mg/liter of cef-
triaxone. The plates were forwarded to the Institut Pas-
teur of Madagascar within 4 hours for 24- to 48-hour
incubation at 37°C. All GNB isolates were identified by
Gram staining, and by API 20E and API 20NE system
(bioMérieux, Marcy l'Etoile, France). The isolates were
then screened for ESBL production using both the resis-
tance phenotype and the double-disk synergy test using
conventional combination: cefotaxime, ceftazidime, cef-
triaxone and amoxicillin-clavulanic acid [2,12]. The
organisms were considered to be producing ESBL when
the zone of inhibition around any of the expanded-spec-
trum cephalosporin discs showed a clear-cut increase
towards the clavulanic acid disc. For E cloacae strains,
this was confirmed by the double disc potentiation test
using a cefepime and clavulanic disc. Phenotypic disc
confirmatory test was performed as recommended by the
Clinical and Laboratory Standards Institute (CLSI -2005).
Antibiotic susceptibility was tested by the standard disk
diffusion method with OSIRIS system (Biorad, Marne la
Coquette, France) on Mueller-Hinton agar, as recom-
mended by the Antibiogram Committee of the French
Microbiology Society (ACFMS) for the characterization
of ESBLs [3]. Amoxicillin, ticarcillin, gentamicin,
tobramycin, amikacin, imipenem, nalidixic acid, cipro-
floxacin, cotrimoxazole were also tested to determine the
resistance patterns of the isolates.
Statistical analysis
Data entry and analysis were performed with Statistica
Software, version 5.5 (Statsoft Corporation, OK, USA).
The Chi-square test and Fisher's exact test were used for
univariate analysis, with the ANOVA and Kruskall Wallis
tests used for comparison of medians. P-values <0.05
were considered to be statistically significant. Explana-
tory variables associated with a p-value less than 0.20
were analyzed by logistic regression to investigate the
confounding factors.
Ethical clearance
The study was approved by the Ministry of Health and
the National Ethics Committee of Madagascar. Informed
consent was obtained from at least one parent of each
child hospitalized before enrolment.
Results
Hospital characteristics with respect to patients
Prevalence of ESBL-PE carriage
Patients Thirty-seven patients were already hospitalized
at the start of the study. For these patients, the sex ratio
(male/female) was 1.1 and the mean age was 53.1 months
(95%CI: 33.3-73.0). Twenty patients were infected with
ESBL-PE (54.1%), particularly K. pneumoniae (n = 11)
and E. coli (n = 8).
From March 10 to April 11, 281 patients were admitted
to the pediatric unit. Consent was not obtained for 22
patients (7.8%). Overall, of a possible 259 patients, 15
patients (5.8%) were not included, as they were admitted
to the hospital on the last day of the prospective study.Andriatahina et al. BMC Infectious Diseases 2010, 10:204
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Of the 244 patients that were included in the cohort, 90
(36.8%) could not be sampled on discharge for various
reasons: 17 (18.8%) died during hospitalization, 19
(21.1%) left the unit without medical advice and 54
(60.0%) were hospitalized for less than 48 h. Rectal swabs
were collected for 154 (63.1%) patients on discharge.
Cohort (244 patients) characteristics included a sex
ratio of 1.25, a mean age of 38.3 months (95%CI: 83.1-
95.5). For all the patients included and discharged before
the end of the study, the mean length of hospital stay was
5.7 days (95% CI: 5.2-6.2). Main admitting diagnoses
included respiratory (31.5%), infectious (20.9%), digestive
(12.3%) and nutritional disorders (15.2%). On admission,
none diagnosed infection was in relation with ESBL-pro-
ducing microorganism. A total of 54/244 patients (22.1%)
were detected as ESBL-PE carriers on admission, and 88/
154 (57.1%) were ESBL-PE carriers on discharge (p-value
for trend <0.001). Among the ESBLE-PE carriers on
admission (n = 54), 34 could be sampled on discharge.
Among the 31 that were still ESBL-PE carriers; 12 (38.7%)
harbored a different organism. On discharge among the
120 sampled patients who were not carriers on admis-
sion, 57 (47.5%) were detected as ESBL-PE carriers (Fig-
ure 1).
Carriage rates on admission and discharge did not dif-
fer according to the age groups (table 1), but the relative
risk of hospital acquisition was significantly higher in the
5-9 year-old group (RR = 6.1 [95%CI: 1.9-19.4]).
Medical Staff Among the medical staff (Table 2), 39 of 52
individuals (75.0%) agreed to participate in the study.
ESBL-PE, E. coli (n = 9) and K. pneumoniae (n = 9), were
detected in the rectal swab cultures from 19 medical staff
(48.7%). Carriage rates did not differ according to the
period of the study.
Environmental sample At least one isolate of ESBL-PE
was detected in each room sampled during the study. Of
the 13 positive samples (Table 2), the main species were
K. pneumoniae (n = 5), Enterobacter cloacae (n = 4) and
E. coli (n = 4). K. pneumonia were detected in each care
room,  E.Coli and  E. Cloacae in three of the four care
rooms. No ESBL-PE isolate was detected during the sec-
ond week of the study.
Characteristics of ESBL-PE isolates
At all 233 ESBL-PE isolates were found: K. pneumoniae
(47.2%), E. coli (32.2%) E. cloacae (12.0%) and other enter-
obacteriaceae (8.6%) (Table 2).
On admission, E. coli and K. pneumoniae was the most
frequent ESBL-PE identified (36.9%, 24/65), whereas K.
pneumoniae was the predominant species on discharge
(52.7%, 58/110), in patients already hospitalized at the
start of the study (55%, 11/20), in medical staff (45.0%, 9/
20), in environment (38.5%, 5/13) and in nosocomial
infection (60.0%, 3/5) (Table 2).
All isolates showed similar resistance patterns. All were
susceptible to imipenem and amikacin with cross-resis-
tance to trimethoprim-sulfamethoxazole (91.3%), gen-
tamicin (76.1%) and ciprofloxacin (50.0%). K.
pneumoniae  isolates were significantly less resistant to
ciprofloxacin than E. coli isolates (34.5% vs 68.4%; p-value
< 0.001).
Community and hospital acquired strains had the same
resistance profile (Table 3).
Risk factors for ESBL-PE carriage
In univariate analysis, significant risk factors for ESBL-PE
carriage on admission were prior hospitalization, use of
invasive devices in the last 30 days, and infection upon
admission (Table 4). In multivariate analysis, four vari-
ables were first included in the model: Patient origin,
prior hospitalization, use of invasive devices in the last 30
days, infection upon admission. Using backward stepwise
procedure, prior hospitalization in the last 30 days
(adjusted OR = 7.4 [95%CI: 2.9-18.3]) was the only inde-
pendent risk factor for ESBL-PE carriage.
Significant risk factors for ESBL-PE hospital acquisition
in univariate analysis were antibiotic therapy and intra-
muscular injections (Table 5). Ages of patients did not
differ between ESBL-PE carriers (mean: 34.2 months) and
non carriers (mean: 39.6 months). In multivariate analy-
sis, five variables were first included in the model: antibi-
otic therapy, intracranial catheter, brachial catheter,
intramuscular injections and care rooms used. After
backward stepwise procedure, antibiotic therapy
(adjusted OR = 4.1 [95%CI: 1.8-9.4]) was the only inde-
pendent risk factor for ESBL-PE acquisition.
During hospitalization, 64.2% of the patients were
treated by antibiotic therapy. The average number of anti-
biotics prescribed by patient was 1.2 (95%CI: 1.0-1.4). For
patients with ESBL-PE carriage on discharge the average
number of antibiotics prescribed was significantly higher
than in patients with no-ESBL-PE carriage (1.7 vs 0.9; p-
Figure 1 Included patients distribution according to ESBL-PE car-
riage status on admission and on discharge.Andriatahina et al. BMC Infectious Diseases 2010, 10:204
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value < 0.01). Overall, 46.8% of patients received more
than one antibiotic. The antibiotic therapy included
ampicillin (38.7%), ceftriaxon (29.4%) and gentamicin
(27.8%). In backward stepwise logistic regression analysis,
ampicillin (adjusted OR = 3.9 [95%CI: 1.6-9.9]) was the
only antibiotic in relation with ESBL-PE acquisition (table
5).
Nosocomial infections
During the study, six hospital-acquired infections
occurred among the 190 patients hospitalized for more
than 48 hours. The incidence rate was estimated at 3.1%
during the study period. The major cause of infection was
intravenous catheters (n = 4). None of the six patients
were ESBL-PE carriers on admission.
K. pneumoniae (n = 3), Pantoea sp (n = 2), Acineto-
bacter baumanii (n = 1) were isolated. All K. pneumoniae
and Pantoea sp were ESBL-PE but remained susceptible
to amikacin and imipenem in all cases.
Discussion
This study aimed to evaluate the intestinal carriage of
ESBL-PE in children hospitalized in the JRB Hospital of
Antananarivo, to develop a preventive strategy for con-
trolling the spread of multiresistant bacteria in the pedi-
atric ward. Our results confirm previous findings
showing high levels of gut colonization by ESBL-PE in
hospitals of low-income countries [3], and raises special
concerns about the community spread of these multidrug
resistant bacteria in Madagascar.
On admission, a carriage rate greater than 20% suggests
prior acquisition via the community. Interestingly,
although history of hospitalization appeared to be a risk
factor, 74.1% of ESBL-PE carriers had not been hospital-
ized during the previous 30 days (Table 4), demonstrating
that the community compartment is essential for the
maintenance of ESBL-PE. Of the 154 patients sampled on
discharge after more than 48 hours of hospitalization, the
carriage rate exceeded 50%. The independent risk factors
associated with ESBL-PE carriage were however known.
Table 1: ESBL carriage rate on admission and discharge as a function of age group
Age group On admission On discharge RR [95%CI]
NE S B L  +  ( % ) NE S B L  +  ( % )
0-4 years 182 44 (24.2) 115 70 (60.8) 2.5 [1.9 - 3.5]
5-9 years 35 3 (8.5) 21 11 (52.4) 6.1 [1.9 - 19.4]
≥10 years 27 7 (25.9) 18 7 (38.8) 1.5 [0.7 - 3.5]
Total 244 54 (22.1) 154 88 (57.1) 2.6 [2.0 - 3.5]



















hospitalized at the 
beginning of the 
study
37 20 (54.1) 20 8 (40.0) 11 (55.0) 1 (5.0) 0
Patients on 
admission
244 54 (22.1) 65 24 (36.9) 24 (36.9) 11 (16.9) 6 (9.2)
Patients on 
discharge
154 88 (57.1) 110 30 (27.3) 58 (52.7) 11 (10.0) 11 (10.0)
Medical 
Staff
39 19 (48.7) 20 9 (45.0) 9 (45.0) 1 (5.0) 1 (5.0)
Environmental 
samples
100 13 (13.0) 13 4 (30.8) 5 (38.5) 4 (30.8) 0
Nosocomial 
infections
7 6 (85.7) 5 0 3 (60.0) 0 2 (40.0)
Total 578 200 (34.6) 233 75 (32.2) 110 (47.2) 28 (12.0) 20 (8.6)Andriatahina et al. BMC Infectious Diseases 2010, 10:204
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Table 3: Antimicrobial resistance of ESBL-producing E. Coli and K. Pneumoniae isolates from community or acquired 
during hospitalization (number of tested isolates in brackets)
Drugs
AMX TIC AMC CAZ GEN TOB AMK IMP NAL CIP TMP
Community strains - On admission without prior hospitalization history
E. coli (n = 15) % 100.0 100.0 100.0 93.3 73.3 80.0 0.0 0.0 86.7 60.0 93.3
K.Pneumoniae (n = 15) % 100.0 100.0 100.0 86.7 80.0 86.7 0.0 0.0 40.0 33.3 93.3
Hospital-acquired strains - On discharge ESBL-PE negative on admission
E. coli (n = 19) % 100.0 100.0 100.0 100.0 94.7 100.0 0.0 0.0 94.7 78.9 89.5
K.Pneumoniae (n= 39) % 100.0 100.0 100.0 79.4 89.7 89.7 0.0 0.0 46.1 35.8 100.0
AMX:Amoxicillin, TIC:Ticarcillin, AMC: Amoxicillin+Clavulanic Acid, CAZ: Ceftazidime, GEN: Gentamicin, TOB:Tobramycin, AMK: Amikacin, IMP: 
Imipenem, NAL: Nalidixic Acid, CIP: Ciprofloxacin, TMP: Trimethoprim/Sulfamethoxazole.
Table 4: Analysis of the risk factors on admission
Total (n = 244) ESBL + (n = 54)
N( % ) N( % )O R p - v a l u e
Sex
Male 136 (55.7) 32 (59.2) 1.3 0.5
Age group (months)
<1 31 (12.7) 6 (11.1) 0.31
1 to 12 84 (34.4) 25 (46.3)
13 to 24 37 (15.2) 8 (14.8)
25 to 35 22 (9.0) 4 (7.5)
≥ 3 6 7 0( 2 8 . 7 ) 1 1( 2 0 . 3 )
Mean age [95%CI] 35.6 [29.7-41.6] 33.3 [19.2-47.4] 0.86
Patient origin
H o u s e 7 3( 2 9 . 9 ) 1 5( 2 7 . 8 ) 0 . 2
Primary Health centre 149 (61.0) 31 (57.4)
Other unit or hospital 22 (9.0) 8 (14.8)
Last 30 days history
Hospitalization 23 (9.4) 14 (25.9) 7.4 <0.01
Invasives devices used 15 (6.1) 11 (20.3) 10.8 <0.01
Antibiotic therapy 100 (40.9) 22 (40.7) 1.0 0.9
Admitting diagnoses
Respiratory 84 (31.5) 19 (35.2) 0.8 0.5
Digestive 39 (12.3) 9 (16.6)
Malnutrition 37 (15.2) 10 (18.5)
Neurological 49 (20.1) 8 (14.8)
Infection upon admission 51 (20.9) 19 (37.3) 1.3 <0.01Andriatahina et al. BMC Infectious Diseases 2010, 10:204
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Thus, previously hospitalized patients receiving antibi-
otic therapy, especially ampicillin, are the patients most
likely to be affected. Additional risk results from place-
ment of indwelling devices (catheters). Moreover, 48.7%
healthy medical staffs were carriers, and, 22% of the envi-
ronmental samples were positive, indicating poor hospi-
tal hygiene.
Swabs were plated on Drigalski agar supplemented with
3 mg/liter ceftriaxon; this led to the selection of not only
ESBL-PE, but also to all GNB resistant to third generation
cephalosporins, including non-fermentative species as P.
aeruginosa  or  Acinetobacter baumannii. Although the
recommended selective media is Drigalski agar supple-
mented with cefotaxime 0.5 mg/liter or MacConkey agar
supplemented with ceftazidime 4 mg/liter, ceftriaxone
was chosen, as it is the only third generation cepha-
losporin available in Madagascar. The concentration of 3
mg/liter was adjusted by pretesting, to improve specific-
ity of the screening. It is therefore likely that the true
prevalence rates of ESBL-PE carriage were higher than
those found, already well above the rates reported else-
where. Conversely, studies conducted from 1993 to 1997
in Finland [13] or from 1997 to 1999 in Spain [14] showed
that stool cultures contained no ESBL-producing isolates
when performed on antibiotic-free agar plates.
A weakness of the study was that we were unable to
sample all of the patients on discharge, diminishing the
strength of the statistical analysis. However, the rate of
50% for ESBL-PE carriage on discharge, in a non epi-
demic context, matched well that of inpatients sampled at
the beginning of the study.
Asymptomatic colonization of the intestinal mucosa
with ESBL-producing GNB has been previously
described [15-17]. Several surveys, conducted during
nosocomial infection outbreaks, revealed the spread of
multiresistant strains within the ward, including the
spread to other wards of the hospital due to transmission
from patients to others or from staff to patients. In our
study, we were not able to determine the relatedness
between ESBL-PE from different origins, but the origins
are probably various. Rates of ESBL-PE carriage among
hospitalized patients were estimated at 11.7% in Spain
[18], 16% in Lebanon [19], and 26% in Saudi Arabia [20].
A previous prospective study of children in Turkey
revealed that 18.5% of children carry ESBL-producing K.
pneumoniae, the incidence rate of nosocomial infections
due to this strain being 1.6% among hospitalized children
[21].
The rate of 22.1% of ESBL-PE carriage on admission to
the pediatric ward in Antananarivo, largely exceeds that
reported from an intensive care unit in a hospital in Balti-
more (2%) [22], and from a neonatal intensive care unit in
Washington (4.2%) [23]. All these findings and those of
outpatients in Barcelona, Spain (7.5%) [4] raise the ques-
tion of asymptomatic carriage of ESBL-PE in the commu-
nity [7], which enhances the spread of resistance genes by
human-to-human transmission or contamination of the
environment [24,25]. Such a hidden reserve of resistance
Table 5: Analysis of the risk factors during hospitalization
Total (n = 120) ESBL-PE Carriage (n = 57)
n (%) n (%) OR 95%CI p-value
Hospitalization treatments
Antibiotics 77 (64.2) 45 (78.9) 3.5 [1.5-5.9] <0.01
Intracranial catheter 38 (31.7) 22 (38.6) 1.9 [0.9-4.4] 0.08
Brachial catheter 20 (16.7) 13 (22.8) 2.3 [0.8-6.4] 0.1
intramuscular injection 36 (30.0) 24 (42.1) 3.1 [1.4-7.2] <0.01
intravenous injection 10 (8.3) 4 (7.0) 0.7 [0.2-2.7] 0.5
Nasogastric sond 30 (25.0) 16 (28.1) 1.1 [0.7-1.7] 0.7
Moving in unit
rooms 35 (29.2) 17 (29.8) 0.95 [0.6-1.4] 0.7
care rooms 107 (89.2) 54 (94.7) 1.01 [0.6-1.8] 0.9
Care rooms used
Ground floor 7 (5.8) 6 (10.5) 3.63 [0.6-22.4] 0.1
First floor 40 (33.3) 18 (31.6) 1.4 [0.4-5.5] 0.5
Second floor 60 (50.0) 30 (31.6) 1.3 [0.3-5.9] 0.9Andriatahina et al. BMC Infectious Diseases 2010, 10:204
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factors carried by healthy people may help to maintain
high levels of antimicrobial resistance in hospital floras
[26,27]. Under antibiotic selective pressure, especially in
intensive care units [28], intestinal colonization by ESBL-
PE strains is favored among inpatients, increasing the
carriage rates and the risk of nosocomial infections
[29,30]. First-line antibiotic therapies for the treatment of
these infections, such as amikacin and imipenem, are
expensive and difficult to acquire in Madagascar. Most
ESBL-PE isolates are multidrug-resistant strains. Only
54.3% of isolates were susceptible to fluoroquinolones
(FQ) on admission, and 47.8%, on discharge (Table 6).
Previous FQ consumption has been proven to be a risk
factor for acquisition of ESBL-producing strains, espe-
cially those producing CTX-M-type enzymes [29,31].
The significant increase in the prevalence of ESBL-PE
carriage raises the concern of multidrug resistance in
Madagascar. The presence of ESBL-PE complicates the
selection of antibiotics used for the empirical therapy of
community-onset infections. The only effective treat-
ment for these strains (carbapenem and amikacin) (table
3) are not available in Madagascar, as they are too expen-
sive. We fear that the increasing use of broad spectrum
antibiotics may lead to an increased incidence of infec-
tions with ESBL-PE, whose treatment will be increasingly
difficult. There is an urgent need to promote a rational
use of antibiotics, both in hospital and in the community,
the development of new generic drugs, and strict per-
sonal hygiene to prevent the selection and the spread of
these strains.
Conclusions
Nosocomial infections and antimicrobial resistance have
become increasing challenges in low-income countries.
The detection and quarantine of patients with ESBL-PE
on admission to hospital are no longer adequate mea-
sures if a significant rate of carriage is highlighted in the
community. Further studies are needed to quantify the
prevalence of ESBL-PE carriage in the Malagasy popula-
tion and to identify its determinants. The epidemic
spread of resistance factors knows no borders. Interna-
tional collaboration is needed to help developing coun-
tries respond to the threat of infection with multidrug
resistant bacteria.
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